Publication of List of Manufacturers Revoked from Licensing for the Manufacture of Therapeutic Goods

Overview

The Therapeutic Goods Act 1989 was enacted to ensure that therapeutic goods available in Australia are of acceptable quality, safety, and efficacy. This Act was introduced to address gaps in the regulation and oversight of therapeutic goods, encompassing medicines, medical devices, blood, and tissues, with a focus on protecting public health by maintaining stringent standards. The enactment of this legislation by the Commonwealth Parliament aimed to create a robust regulatory framework that governs the supply, advertising, and manufacturing of therapeutic goods, ultimately to safeguard consumers from substandard or unsafe products. The policy objective of the Therapeutic Goods Act 1989 is to maintain and improve the health and safety of the Australian public by ensuring that therapeutic goods are of high quality and pose minimal risk when used as intended.

Scope and Application

The Therapeutic Goods Act 1989 applies to any person or entity involved in the manufacture, supply, advertising, or importation of therapeutic goods in Australia. Therapeutic goods encompass a wide range of products, including medicines, medical devices, blood and blood components, and other health-related products. The Act regulates these goods to ensure they meet safety, quality, and efficacy standards, thus protecting public health. The application of the Act extends to all states and territories within Australia, thereby covering both Commonwealth and state jurisdictions. However, certain classes of goods, such as those specifically exempted under the Act, may not fall under its purview. The Act also allows for the creation of subordinate instruments that can further extend or restrict its application, ensuring that the regulation of therapeutic goods is comprehensive and adaptable to new challenges and discoveries in the health sector. The revocation of a licence to manufacture therapeutic goods, as seen in the case of the Australian Red Cross Blood Service, is an example of the Act's enforcement mechanism to maintain high standards within the industry.

Key Provisions

The Therapeutic Goods Act 1989, as highlighted in this gazette, primarily focuses on the revocation of licences for the manufacture of therapeutic goods. Specifically, section 41(1)(d) of the Act allows the Secretary to revoke a manufacturer's licence, and in this instance, the licences held by The Australian Red Cross Blood Service have been revoked at the request of the manufacturer. This revocation pertains to two specific locations: the Blood Donor Centre at 20 Elizabeth Street, Sydney, NSW, and the Blood Donor Centre at Pelican Plaza, Shop 13A, 1007 North East Road, Ridgehaven, SA. The licences in question are MI-31072007-LI-001991-11 and MI-07022007-LI-001721-11 respectively. This revocation imposes significant obligations on the manufacturer, The Australian Red Cross Blood Service. The primary obligation is the cessation of all manufacturing activities related to therapeutic goods at the specified locations. The manufacturer must ensure that no further therapeutic goods are produced, packaged, or labelled from these sites. Compliance with this revocation is crucial to avoid further legal repercussions. Additionally, the manufacturer is required to notify all relevant stakeholders of the revocation and take steps to secure or dispose of any remaining stock in compliance with the Act. Failure to comply with the provisions of the Therapeutic Goods Act 1989 can result in severe consequences. The Act outlines various offences, and breaches related to manufacturing without a valid licence can lead to significant penalties. Under section 41(4) of the Act, a person who contravenes a requirement of the Act can face substantial fines. For corporate entities, the maximum penalty can reach up to $2,100,000. Additionally, individuals responsible for the contravention may face penalties of up to $210,000, along with potential imprisonment terms. These penalties underscore the seriousness with which the Act treats non-compliance, highlighting the importance of adhering to the legislative requirements.